Home LiteratureArticle Details
PMID: 24973356 Published · ppublish English Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies.

Human molecular genetics ·Vol. 23 ·No. 23 ·2014-12-01 ·Pages 6139-46

Bras J, Guerreiro R, Darwent L, Parkkinen L, Ansorge O, Escott-Price V, Hernandez DG, Nalls MA, Clark LN, Honig LS, Marder K, Van Der Flier WM, Lemstra A, Scheltens P, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Ortega-Cubero S, Pastor P, Ferman TJ, Graff-Radford NR, Ross OA, Barber I, Braae A, Brown K, Morgan K, Maetzler W, Berg D, Troakes C, Al-Sarraj S, Lashley T, Compta Y, Revesz T, Lees A, Cairns N, Halliday GM, Mann D, Pickering-Brown S, Dickson DW, Singleton A, Hardy J

Abstract

Clinical and neuropathological similarities between dementia with Lewy bodies (DLB), Parkinson's and Alzheimer's diseases (PD and AD, respectively) suggest that these disorders may share etiology. To test this hypothesis, we have performed an association study of 54 genomic regions, previously implicated in PD or AD, in a large cohort of DLB cases and controls. The cohort comprised 788 DLB cases and 2624 controls. To minimize the issue of potential misdiagnosis, we have also performed the analysis including only neuropathologically proven DLB cases (667 cases). The results show that the APOE is a strong genetic risk factor for DLB, confirming previous findings, and that the SNCA and SCARB2 loci are also associated after a study-wise Bonferroni correction, although these have a different association profile than the associations reported for the same loci in PD. We have previously shown that the p.N370S variant in GBA is associated with DLB, which, together with the findings at the SCARB2 locus, suggests a role for lysosomal dysfunction in this disease. These results indicate that DLB has a unique genetic risk profile when compared with the two most common neurodegenerative diseases and that the lysosome may play an important role in the etiology of this disorder. We make all these data available.

MeSH Terms
Alzheimer Disease/etiology,genetics,pathology Apolipoproteins E/genetics Case-Control Studies Cohort Studies Female Genetic Association Studies Genetic Loci Humans Lewy Body Disease/etiology,genetics,pathology Lysosome-Associated Membrane Glycoproteins/genetics Lysosomes/pathology Male Parkinson Disease/etiology,genetics,pathology Receptors, Scavenger/genetics Risk Factors alpha-Synuclein/genetics
Chemicals
Apolipoproteins E Lysosome-Associated Membrane Glycoproteins Receptors, Scavenger SCARB2 protein, human SNCA protein, human alpha-Synuclein
Authors & Affiliations
42 authors, click to expand affiliations / ORCID
Bras Jose
Department of Molecular Neuroscience, j.bras@ucl.ac.uk.
Guerreiro Rita
Department of Molecular Neuroscience.
Darwent Lee
Department of Molecular Neuroscience.
Parkkinen Laura
Nuffield Department of Clinical Neurosciences, Oxford Parkinson's Disease Centre, University of Oxford, Oxford, UK.
Ansorge Olaf
Nuffield Department of Clinical Neurosciences, Oxford Parkinson's Disease Centre, University of Oxford, Oxford, UK.
Escott-Price Valentina
MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, UK.
Hernandez Dena G
Laboratory of Neurogenetics, National Institutes on Aging, NIH, Bethesda, USA.
Nalls Michael A
Laboratory of Neurogenetics, National Institutes on Aging, NIH, Bethesda, USA.
Clark Lorraine N
Taub Institute for Alzheimer Disease and the Aging Brain, Department of Pathology and Cell Biology, and.
Honig Lawrence S
Taub Institute for Alzheimer Disease and the Aging Brain, Department of Neurology, Columbia University, New York, NY, USA.
Marder Karen
Taub Institute for Alzheimer Disease and the Aging Brain, Department of Neurology, Columbia University, New York, NY, USA.
Van Der Flier Wiesje M
Department of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands.
Lemstra Afina
Department of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands.
Scheltens Philip
Department of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands.
Rogaeva Ekaterina
Department of Medicine, Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
St George-Hyslop Peter
Department of Medicine, Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada, Cambridge Institute for Medical Research, and Cambridge National Institute of Health Research Biomedical Research Unit in Dementia, University of Cambridge, Cambridge CB2 0XY, UK.
Londos Elisabet
Clinical Memory Research Unit, Institute Clinical Sciences Malmö, Lund University, Sweden.
Zetterberg Henrik
Department of Molecular Neuroscience, Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Ortega-Cubero Sara
Neurogenetics Laboratory, Division of Neurosciences, Center for Applied Medical Research, University of Navarra, Pamplona, Spain, Department of Neurology, Clínica Universidad de Navarra, University of Navarra School of Medicine, Pamplona, Spain, CIBERNED, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.
Pastor Pau
Neurogenetics Laboratory, Division of Neurosciences, Center for Applied Medical Research, University of Navarra, Pamplona, Spain, Department of Neurology, Clínica Universidad de Navarra, University of Navarra School of Medicine, Pamplona, Spain, CIBERNED, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.
Ferman Tanis J
Department of Psychiatry, Department of Psychology.
Graff-Radford Neill R
Department of Neurology and.
Ross Owen A
Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Barber Imelda
Translation Cell Sciences - Human Genetics, School of Life Sciences, Queens Medical Centre, University of Nottingham, Nottingham, UK.
Braae Anne
Translation Cell Sciences - Human Genetics, School of Life Sciences, Queens Medical Centre, University of Nottingham, Nottingham, UK.
Brown Kristelle
Translation Cell Sciences - Human Genetics, School of Life Sciences, Queens Medical Centre, University of Nottingham, Nottingham, UK.
Morgan Kevin
Translation Cell Sciences - Human Genetics, School of Life Sciences, Queens Medical Centre, University of Nottingham, Nottingham, UK.
Maetzler Walter
Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, Center of Neurology, University of Tuebingen, and DZNE, German Center for Neurodegenerative Diseases, Tuebingen, Germany.
Berg Daniela
Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, Center of Neurology, University of Tuebingen, and DZNE, German Center for Neurodegenerative Diseases, Tuebingen, Germany.
Troakes Claire
MRC London Neurodegenerative Diseases Brain Bank, Department of Clinical Neuroscience, King's College London, Institute of Psychiatry, London, UK.
Al-Sarraj Safa
MRC London Neurodegenerative Diseases Brain Bank, Department of Clinical Neuroscience, King's College London, Institute of Psychiatry, London, UK.
Lashley Tammaryn
Queen Square Brain Bank, Department of Molecular Neuroscience, and.
Compta Yaroslau
Queen Square Brain Bank, Department of Molecular Neuroscience, and Parkinson's disease and Movement Disorders Unit, Neurology Service, IDIBAPS, CIBERNED, Hospital Clínic, Barcelona, Catalonia, Spain.
Revesz Tamas
Queen Square Brain Bank, Department of Molecular Neuroscience, and.
Lees Andrew
Queen Square Brain Bank, Department of Molecular Neuroscience, and.
Cairns Nigel
Knight Alzheimer's Disease Research Center and Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.
Halliday Glenda M
Neuroscience Research Australia, Sydney, Australia, School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, Australia.
Mann David
Institute of Brain, Behaviour and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK and.
Pickering-Brown Stuart
Institute of Brain, Behaviour and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK and.
Dickson Dennis W
Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Singleton Andrew
Laboratory of Neurogenetics, National Institutes on Aging, NIH, Bethesda, USA.
Hardy John
Reta Lila Weston Research Laboratories, Department of Molecular Neuroscience, UCL Institute of Neurology, London WC1N 3BG, UK.
References (31)
31 references, click to expand
  1. Best practices and joint calling of the HumanExome BeadChip: the CHARGE Consortium.
    PLoS One. 2013 Jul 12;8(7):e68095 PMID: 23874508
  2. Pathological entity of dementia with Lewy bodies and its differentiation from Alzheimer's disease.
    Acta Neuropathol. 2004 Aug;108(2):121-8 PMID: 15235805
  3. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.
    Nat Genet. 2009 Oct;41(10):1088-93 PMID: 19734902
  4. Genome-wide association study reveals genetic risk underlying Parkinson's disease.
    Nat Genet. 2009 Dec;41(12):1308-12 PMID: 19915575
  5. Dementia with Lewy bodies.
    Br J Psychiatry. 2002 Feb;180:144-7 PMID: 11823325
  6. Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease.
    Am J Hum Genet. 2004 Jun;74(6):1121-7 PMID: 15122513
  7. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.
    Neurology. 2005 Dec 27;65(12):1863-72 PMID: 16237129
  8. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.
    Neurology. 1996 Nov;47(5):1113-24 PMID: 8909416
  9. Motor signs during the course of Alzheimer disease.
    Neurology. 2004 Sep 28;63(6):975-82 PMID: 15452286
  10. The progression of pathology in longitudinally followed patients with Parkinson's disease.
    Acta Neuropathol. 2008 Apr;115(4):409-15 PMID: 18231798
  11. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years.
    Mov Disord. 2008 Apr 30;23(6):837-44 PMID: 18307261
  12. What are the relations between Lewy body disease and AD?
    J Neural Transm Suppl. 1998;54:107-16 PMID: 9850919
  13. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.
    Nat Genet. 2013 Dec;45(12):1452-8 PMID: 24162737
  14. Apolipoprotein E4 and Alzheimer's disease pathology in Lewy body disease and in other beta-amyloid-forming diseases.
    Lancet. 1994 May 7;343(8906):1155 PMID: 7818636
  15. Genetics of Parkinson's disease: LRRK2 on the rise.
    Brain. 2005 Dec;128(Pt 12):2760-2 PMID: 16311269
  16. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.
    Nat Genet. 2011 May;43(5):436-41 PMID: 21460841
  17. APOE ε4 increases risk for dementia in pure synucleinopathies.
    JAMA Neurol. 2013 Feb;70(2):223-8 PMID: 23407718
  18. Analysis of genome-wide association studies of Alzheimer disease and of Parkinson disease to determine if these 2 diseases share a common genetic risk.
    JAMA Neurol. 2013 Oct;70(10):1268-76 PMID: 23921447
  19. A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder.
    Brain. 2007 Sep;130(Pt 9):2277-91 PMID: 17681982
  20. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.
    Neurology. 2007 Mar 13;68(11):812-9 PMID: 17353469
  21. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.
    Lancet. 2011 Feb 19;377(9766):641-9 PMID: 21292315
  22. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies.
    JAMA Neurol. 2013 Jun;70(6):727-35 PMID: 23588557
  23. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.
    N Engl J Med. 2009 Oct 22;361(17):1651-61 PMID: 19846850
  24. Apolipoprotein E4 frequencies in a Japanese population with Alzheimer's disease and dementia with Lewy bodies.
    PLoS One. 2011 Apr 28;6(4):e18569 PMID: 21552550
  25. Senile dementia of the Lewy body type has an apolipoprotein E epsilon 4 allele frequency intermediate between controls and Alzheimer's disease.
    Neurosci Lett. 1994 Nov 21;182(1):1-2 PMID: 7891871
  26. The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease.
    Mov Disord. 2013 Feb;28(2):232-236 PMID: 23225227
  27. Glucocerebrosidase mutations and the pathogenesis of Parkinson disease.
    Ann Med. 2013 Dec;45(8):511-21 PMID: 24219755
  28. PLINK: a tool set for whole-genome association and population-based linkage analyses.
    Am J Hum Genet. 2007 Sep;81(3):559-75 PMID: 17701901
  29. Association of glucocerebrosidase mutations with dementia with lewy bodies.
    Arch Neurol. 2009 May;66(5):578-83 PMID: 19433657
  30. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease.
    Nat Genet. 2009 Oct;41(10):1094-9 PMID: 19734903
  31. Dementia with Lewy bodies: diagnosis and management.
    Int J Geriatr Psychiatry. 2001 Dec;16 Suppl 1:S12-8 PMID: 11748785
Article Info
Journal
Human molecular genetics
Abbr.
Hum Mol Genet
ISSN
1460-2083
Published
2014-12-01
Epub
2014-00-27
Pages
6139-46
Language
English
Region
England
NLM ID
9208958
PMCID
PMC4222357
Subset
IM
Grants
NINDS NIH HHS · R01 NS078086 · United States
Parkinson's UK · G-0907 · United Kingdom
Medical Research Council · G0701075 · United Kingdom
CIHR · Canada
Medical Research Council · MC_G1000735 · United Kingdom
NINDS NIH HHS · P50 NS072187 · United States
NCATS NIH HHS · UL1TR000040 · United States
Medical Research Council · MR/L016397/1 · United Kingdom
Medical Research Council · MR/L010305/1 · United Kingdom
Wellcome Trust · 089701 · United Kingdom
NINDS NIH HHS · NS060113 · United States
NIA NIH HHS · P50AG008702 · United States
Wellcome Trust · 089703 · United Kingdom
NIA NIH HHS · AG000951-12 · United States
Wellcome Trust · 089698 · United Kingdom
Wellcome Trust · 100140 · United Kingdom
NINDS NIH HHS · P50NS038370 · United States
Wellcome Trust · 081864 · United Kingdom
Medical Research Council · MR/L022656/1 · United Kingdom
Parkinson's UK · K-1204 · United Kingdom
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com